Sonnet BioTherapeutic Stock Forum

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Wednesday, 26th February at 9:00 am
Poster presented at the 2025 AACR:IO Conference
Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced targeting to the tumor microenvironment...

$Sonnet BioTherapeutic (SONN.US)$ Reuters· 3 mins ago
Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
Tuesday, 28th January at 9:05 am
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteins
In addition to the U.S. and EU, Sonnet's global IP coverage
now extends to China, Japan, Russia and New Zealand
Management releases "What This Mea...

$Sonnet BioTherapeutic (SONN.US)$ Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)".
Benzinga· just

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
Tuesday, 21st January at 9:05 am
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with the potential to improve trabectedin's therapeutic window in soft-tissue sarcoma patients
Combined mechan...

$Citius Oncology (CTOR.US)$ $Alpha Modus Holdings (AMOD.US)$ $Pop Culture (CPOP.US)$ $Immuron (IMRN.US)$ $Ming Shing Group (MSW.US)$ $Healthcare Triangle (HCTI.US)$ $Innovative Eyewear (LUCY.US)$ $MetaVia (MTVA.US)$ $Advent Technologies (ADN.US)$ $Baosheng Media Group (BAOS.US)$ $Sonnet BioTherapeutic (SONN.US)$ $FOUNDER GROUP LIMITED (FGL.US)$ $PTL Ltd (PTLE.US)$ $Regional Health Properties (RHE.US)$
📊⚡️📊

$Sonnet BioTherapeutic (SONN.US)$
any chance of rise short term?

$Sonnet BioTherapeutic (SONN.US)$ scam

$Sonnet BioTherapeutic (SONN.US)$
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered into a definitive agreement with institutional investors for the purchase and sal...